Patients with newly diagnosed low- or intermediate-risk prostate cancer who require or choose active treatment and are not considering or are not suitable for active surveillance. | |
| |
Low-risk defined as: | Intermediate-risk defined as: |
• PSA <10 ng/mL | • PSA ≥ 10 ng/mL, but <20 ng/mL |
• clinical stage T1c-T2a | • or clinical stage T2b-T2c |
• Gleason score <7 | • or Gleason score =7 |
PSA: prostate-specific antigen.